Scientific article
Open access

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients

Published inAlzheimer's research & therapy, vol. 9, no. 1, 38
Publication date2017-06-06
First online date2017-06-06

Background: Pyroglutamylation of truncated Aβ peptides, which is catalysed by enzyme glutaminyl cyclase (QC), generates pE-Aβ species with enhanced aggregation propensities and resistance to most amino-peptidases and endo-peptidases. pE-Aβ species have been identified as major constituents of Aβ plaques and reduction of pE-Aβ species is associated with improvement of cognitive tasks in animal models of Alzheimer's disease (AD). Pharmacological inhibition of QC has thus emerged as a promising therapeutic approach for AD. Here, we question whether cerebrospinal fluid (CSF) QC enzymatic activity differs between AD patients and controls and whether inflammatory or angiogenesis mediators, some of which are potential QC substrates, and/or Aβ peptides may serve as pharmacodynamic read-outs for QC inhibition.

Methods: QC activity, Aβ peptides and inflammatory or angiogenesis mediators were measured in CSF of a clinically well-characterized cohort of 20 mild AD patients, 20 moderate AD patients and 20 subjective memory complaints (SMC) controls. Correlation of these parameters with core diagnostic CSF AD biomarkers (Aβ42, tau and p-tau) and clinical features was evaluated.

Results: QC activity shows a tendency to decrease with AD progression (p = 0.129). The addition of QC activity to biomarkers tau and p-tau significantly increases diagnostic power (ROC-AUCTAU = 0.878, ROC-AUCTAU&QC = 0.939 and ROC-AUCpTAU = 0.820, ROC-AUCpTAU&QC = 0.948). In AD and controls, QC activity correlates with Aβ38 (r = 0.83, p < 0.0001) and Aβ40 (r = 0.84, p < 0.0001), angiogenesis mediators (Flt1, Tie2, VEGFD, VCAM-1 and ICAM-1, r > 0.5, p < 0.0001) and core diagnostic biomarkers (r > 0.35, p = <0.0057). QC activity does not correlate with MMSE or ApoE genotype.

Conclusions: Aβ38, Aβ40 and angiogenesis mediators (Flt1, Tie2, VEGFD, VCAM-1 and ICAM-1) are potential pharmacodynamic markers of QC inhibition, because their levels closely correlate with QC activity in AD patients. The addition of QC activity to core diagnostic CSF biomarkers may be of specific interest in clinical cases with discordant imaging and biochemical biomarker results.

  • 3pE-Aβ42
  • Alzheimer’s disease
  • Amyloid beta
  • Cerebrospinal fluid
  • Glutaminyl cyclase
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / cerebrospinal fluid
  • Alzheimer Disease / diagnosis
  • Aminoacyltransferases / cerebrospinal fluid
  • Amyloid beta-Peptides / cerebrospinal fluid
  • Angiogenesis Modulating Agents / cerebrospinal fluid
  • Angiogenic Proteins / cerebrospinal fluid
  • Biomarkers / cerebrospinal fluid
  • Disease Progression
  • Enzyme Activation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Statistics as Topic
Affiliation Not a UNIGE publication
  • Schweizerische Multiple Sklerose Gesellschaft -
Citation (ISO format)
BRIDEL, Claire et al. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients. In: Alzheimer’s research & therapy, 2017, vol. 9, n° 1, p. 38. doi: 10.1186/s13195-017-0266-6
Main files (1)
Article (Published version)
Secondary files (4)
ISSN of the journal1758-9193

Technical informations

Creation12/22/2022 1:58:00 PM
First validation12/22/2022 1:58:00 PM
Update time03/16/2023 10:26:08 AM
Status update03/16/2023 10:26:06 AM
Last indexation08/31/2023 10:25:19 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack